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The increasing global incidence and prevalence of non-tuberculous mycobacteria (NTM) 
infection is of growing concern. New evidence of person-to-person transmission of 
multidrug-resistant NTM adds to the global concern. The reason why certain individuals 
are at risk of NTM infections is unknown. Using high definition flow cytometry, we studied 
the immune profiles of two groups that are at risk of Mycobacterium abscessus complex 
infection and matched controls. The first group was cystic fibrosis (CF) patients and the 
second group was elderly individuals. CF individuals with active M. abscessus complex 
infection or a history of M. abscessus complex infection exhibited a unique surface T cell 
phenotype with a marked global deficiency in TNFα production during mitogen stimu-
lation. Importantly, immune-based signatures were identified that appeared to predict 
at baseline the subset of CF individuals who were at risk of M. abscessus complex 
infection. In contrast, elderly individuals with M. abscessus complex infection exhibited 
a separate T  cell phenotype underlined by the presence of exhaustion markers and 
dysregulation in type 1 cytokine release during mitogen stimulation. Collectively, these 
data suggest an association between T  cell signatures and individuals at risk of M. 
abscessus complex infection, however, validation of these immune anomalies as robust 
biomarkers will require analysis on larger patient cohorts.
Keywords: non-tuberculous mycobacteria, cystic fibrosis, immunoprofiling, pulmonary non-tuberculous 
mycobacteria infection, T cells
inTrODUcTiOn
Pulmonary infection caused by non-tuberculous mycobacteria (NTM) is an emerging threat with 
serious public health consequences. Mortality rates of 10–40% due to lung disease caused by these 
lesser known “cousins” of Mycobacterium tuberculosis (TB) have been increasingly reported in the 
developed world (1–4). The prolonged treatment regimens lasting months to years and increasing 
antibiotic resistance to front-line antibiotics make these pathogens difficult and expensive infections 
to treat. Over 180 species of NTM are known to cause disease in humans of which the Mycobacterium 
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avium complex (MAC) and the Mycobacterium abscessus com-
plex (MABS) are of dominant clinical interest (5). These species 
account for over 80% of NTM disease worldwide and are among 
the most common causative agents for NTM lung disease (6). The 
global increase in disease prevalence over the past 10–15 years 
has led to an increased focus on patient-oriented research (7, 8).
The emergence and spread of human transmissible clones of 
MABS has been recently reported (9) and is the first evidence 
of person-to-person transmission of NTM that were, up until 
to now, considered environmentally acquired by susceptible 
individuals. MABS infection is associated with rapid decline 
in lung function and extensive lung damage which can be life 
threatening, particularly in patients already compromised with 
respiratory problems such as those with cystic fibrosis (CF). 
Multi-drug resistance (MDR) of these pathogens contributes to 
prolonged and difficult treatment regimens and high relapse rates, 
both of which lead to increased morbidity/mortality and escalat-
ing treatment costs in a group of patients who are already highly 
susceptible to opportunistic infections. The presence of MABS is 
an absolute contradiction to lung transplantation (10–13).
Non-tuberculous mycobacteria infections are also a growing 
health concern among the elderly population. Pre-existing lung 
diseases, such as chronic obstructive pulmonary disease and bron-
chiectasis are known risk factors for developing NTM infection 
as are lung malignancies, immune modulatory treatments, and 
HIV/AIDS (7, 14). The worldwide increase in NTM infections in 
apparently immunocompetent middle aged to elderly patients, 
in the setting of an aging population contributes to an increased 
population of susceptible individuals at-risk of developing NTM 
infection.
Delineating immune function in NTM infection is of fun-
damental interest in order to understand how and why these 
infections: (i) occur in specific at-risk populations; (ii) progress in 
some patients and; (iii) resolve in others. The importance of Th1-
type cell-mediated immunity in anti-mycobacterial immunity is 
well established. Low production of the Th1 cytokines IFNγ and 
TNFα and more recently, low production of IL-17 and IL-10 have 
been associated with NTM infection (15–21).
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), 
programmed cell death protein 1 (PD-1), and T-cell immuno-
globulin domain and mucin domain 3 (TIM-3) are negative 
regulatory check points that are important for T  cell tolerance 
and regulation during the immune response. Widely known for 
their use as targets in cancer immunotherapy (22), these immune 
checkpoints have also been shown to play an important role in 
T cell exhaustion during chronic infections such as TB (23–27). 
The role of these molecules in NTM infection has yet to be 
explored. Information on T  cell “quality” in terms of cytokine 
production is also lacking. Polyfunctional T cells are known to 
determine pathogenesis and disease progression of TB and other 
infectious and immune-related diseases (26, 28–30).
In order to discover new targets for therapeutic intervention 
and rational vaccine design, an improved understanding of the 
molecular and cellular host defense mechanisms that provide 
protective immunity toward NTM is required. The present study 
comprehensively characterized the immune profile of NTM 
patients by performing high-dimensional flow cytometry-based 
analysis in two cohorts of NTM patients. The first group was CF 
patients and the second group was immunocompetent middle 
aged to elderly patients with MABS infection. We show across 
both groups abnormalities in global T cell function that associate 
with individuals at risk of infection.
PaTienTs anD MeThODs
Patient cohorts
Two patient cohorts were studied. The CF patient cohort (n = 24) 
included three groups of patients; (i) CF patients with active 
pulmonary MABS infection (defined as MABS identified by at 
least one positive culture within a 12-month period) n = 6 (CFAct) 
and one with MAC infection; (ii) patients who had a previous 
diagnosis of MABS infection who had undergone treatment and 
were now in remission as defined by at least six clear sputum 
samples (smear and culture negative over a 1-year period; CFPast 
n = 8) and; (iii) patients who were confirmed as having chronic 
Pseudomonas aeruginosa (Pa) infection by the Leeds criteria (31), 
but with no history of or current NTM infection were included as 
a “within-disease” control group (CFControls n = 9). Five of the six 
patients with active MABS infection had chronic Pa infection and 
one had intermittently positive sputum cultures (≤50% of serial 
sputum cultures positive) for Pa. Sex, age, and demographic-
matched healthy controls were recruited from unrelated adult 
volunteers (HCA n = 10). The second patient cohort was elderly 
patients diagnosed with active NTM (NTMAct n = 10) all of whom 
had confirmed MABS infection. Healthy controls (HCB) sex, age, 
and demographic-matched to the NTMAct patients were recruited 
from healthy adult volunteers (n = 10). All samples were obtained 
with written consent and all protocols were approved by the 
Human Research Ethics Committees of the QIMR Berghofer 
Medical Research Institute, The Prince Charles Hospital, and 
Greenslopes Private Hospital, Australia.
Blood samples and Processing
Peripheral blood mononuclear cells (PBMC) were separated from 
venous blood by Ficoll–Paque PLUS (GE Health) density gradi-
ent method and were cryopreserved in R10 medium (RPMI-1640 
containing 10% fetal bovine serum (FBS) with 100 U/ml penicil-
lin and 100 µg/ml streptomycin) supplemented with 10% DMSO 
(Sigma-Aldrich). Thawed cells were rested overnight in R10 
medium at 37°C. Cells were then stained for viability, counted, 
and aliquoted into three 96-well plate. Cells in plate one were 
resuspended in staining buffer (PBS with 2% FBS) and stained 
for direct ex vivo flow cytometric analysis. Cells in plate two and 
three were split into two aliquots and one aliquot was activated 
with PMA ionomycin (PMA/I) (Ebioscience) at 1× final con-
centration in the presence of Brefeldin A 1 μg/ml (Ebioscience) 
and Monensin 0.1 μg/μl (Ebioscience) for 6 h at 37°C. The other 
aliquot was incubated in R10 without PMA/I as an ex vivo base-
line control.
Flow cytometric analysis
The cells in plate one were stained for surface markers delineating 
major immune cell lineages and evaluated for TIM-3 expression. 
TaBle 1 | Table shows demographic of cystic fibrosis (CF) cohorts and elderly 
patient group.
cFact cFPast cFcontrols nTMact
Mean age (SD) 32.6 (13.6) 34.9 (10.4) 33.1 (8.0) 75.6 (9.23)
Male:female 06:01 06:02 06:03 03:07
Non-tuberculous mycobacteria 
(NTM) infection at time of sample
MABS (6) 
MAC (1)a
None None MABS (10)
history of nTM infection
MABS 0 8 0 0
MAC 3b 0 0 3c
Other infections
Pseudomonas aeruginosa 5 8 9 4
Aspergillus spp 0 0 0 1
Burkholderia sppd 0 1 1 0
lung function
>70% FEV1 4 1 3 8
30–70% FEV1 3 6 5 2
<30% FEV1 0 1 1 0
radiographic features
Bronchiectasis 7 8 9 10
CFAct-CF patients with active NTM infection. CFPast-CF patients with past NTM infection. 
Both groups of patients had a history of P. aeruginosa infection. CFControls-control CF 
patients with chronic P. aeruginosa infection. NTMAct-elderly patients with active NTM 
infection. N/A, not applicable; MABS, Mycobacterium abscessus complex; MAC, 
Mycobacterium avium complex.
aOne patient in CFAct group had active MAC infection. This patient was excluded from 
ANOVA and biomarker analysis but included in general profiling analysis. Data point is 
shown as a blue circle in scatter plots for ANOVA analysis in Figures 1A and 2A.
bOne patient in CFAct group had prior history of MAC infection while two subsequently 
developed MAC infection.
cIn NTMAct elderly patient group, one patient had a history of MAC infection prior to 
MABS infection while two others developed MAC infection after treatment of current 
episode of MABS infection.
dBurkholderia cepecia complex.
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Panel one included surface markers αCD4-FITC (BD), αCD8-
Percp-Cy5.5 (Biolegend), αCD16-PECY7 (BD), αCD19-BV421 
(BD), αCD14-APC (BD), and αTIM-3-PE (R&D Systems). Cells 
in plate two were stained with panel 2 which included surface 
markers αCD4-FITC (BD), αCD8-Percp Cy5.5 (Biolegend), 
activation marker αCD25-PE (BD), and exhaustion marker 
αPD-1-BV605 (BD). Staining for intracellular exhaustion marker 
αCLTA-4-BV421 (BD) and nuclear transcription factor αFOXP3-
APC was performed after fixation and permeabilization on ice 
with FOXP3 Permeabilization kit (Ebioscience) according to 
manufacturers’ instructions. Plate three cells were activated with 
PMA/I and incubated with αCD107a-FITC (BD) during activa-
tion. Cells were then washed and resuspended in staining buffer 
and surface staining was performed with panel 3; αCD3-PECY7 
(BD), αCD4-BV711 (BD), and αCD8-Percp-Cy5.5 (BD) markers. 
Intracellular cytokines were stained with αINFγ-AlexaFlour700 
(BD), αTNFα-APC (BD), and αIL-2-PE (BD) after fixation and 
permeabilization with Fix/Perm buffer kit (BD) for intracel-
lular staining. Stained samples were run on a BD LSR Fortessa 
4 laser cytometer (BD). Sample acquisition was performed on 
BD FACSDiva 8.0 (BD) and data were analyzed with FlowJo v10 
(TreeStar) and Cytobank1 for viSNE analysis (32).
statistical analysis
Statistical analysis was performed with SPSS 22, Graphpad 
PRISM (v6.05), and Gmine2 (33). Comparison of means over 
multiple groups was performed using one-way ANOVA tests 
with Tukeys post-hoc comparisons, while comparisons between 
two groups were performed using unpaired t-tests or Wilcoxon 
rank test. Hierarchical clustering and biomarker identification 
was performed in Gmine. Stepwise regression was performed to 
identify variables associated with NTM disease. The patient in 
CFAct group with active MAC infection was excluded from these 
analyses. However, the patients’ data point was included in scatter 
plots as a blue circle to visually demonstrate how active MAC 
infection compares to active MABS infection. Polyfunctionality 
analysis was performed using Pestle and SPICE V53 (34).
resUlTs
Distinct T cell Phenotype in cF Patients 
susceptible to MaBs infection
We first investigated the phenotypic and functional immune 
profiles of PBMCs in CF patients to probe for functional defi-
ciencies that could underlie predisposition to NTM infection. 
Cohorts were categorized as CF with active NTM infection 
(CFAct), CF with a past history of NTM infection (CFPast), CF with 
chronic Pa infection (and no history of NTM infection CFControl) 
and healthy controls (HCA), all matched in both age (ANOVA 
P =  0.350) and gender distribution (Chi-square P =  0.445). 
Demographic and clinical characteristics of patient groups are 
shown in Table 1. All patients had either active or past MABS 
1 www.Cytobank.org.
2 http://cgenome.net/GMine/.
3 https://exon.niaid.nih.gov/spice/.
infection with the exception of one patient who had active MAC 
infection.
Flow cytometric analysis of PBMCs revealed no significant 
differences in the percentage of B  cells (CD19+), total CD4+ 
T  cells (CD3+CD4+), total CD8+ T  cells (CD3+CD8+), or in 
TIM-3 expression levels on cell subsets between the CF patients 
and healthy controls (data not shown). Comparison of Tregs 
(CD4+ CD25+ FOXP3+) between cohorts showed higher percent-
ages in CFAct and CFPast groups compared to the CFControl group 
(Figure 1A). Analysis of the individual expression of activation 
marker CD25 and exhaustion marker CTLA-4 on CD4+ T cells 
revealed significantly higher expression of CD25 and CTLA-4 in 
CFAct group compared to the CFControl group (Figure 1A). Higher 
co-expression of CD25 and CTLA-4 was seen on CD4+ T cells in 
CFAct group compared to the CFControl group and higher percent-
ages of CD25 and CTLA-4 double-negative CD4+ T  cells were 
observed in the CFControl group and HCA group (Figure 1A).
We next compared the overall pattern of immune marker 
expression of the CD4+ and CD8+ T cell compartments in terms 
of surface “phenotypic fingerprint.” Analysis of triple, double, 
single, or nil expression of markers CD25, CTLA-4, and PD-1 on 
CD4+ T cells revealed a common fingerprint in CFAct and CFPast 
groups which was distinct from the CFControl group (Figures 1B,C). 
A higher number of CLTA-4 single-positive cells were seen in 
patients with either active or past NTM infection as compared 
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FigUre 1 | Divergent T cell activation and exhaustion profiles in cystic fibrosis (CF) patients based on non-tuberculous mycobacteria (NTM) infection status.  
(a) Flow cytometric analysis of ex vivo CD4+ T cells show significant differences in Treg percentages and marker expression between patient groups. Significantly 
more Tregs were seen in both CFAct and CFPast groups compared to CFContro1 (one-way ANOVA with post-hoc testing P = 0.013 and P = 0.042, respectively). 
Significantly higher CD25+ CD4+ T cells were observed in both CFAct and CFPast groups compared to CFContro1 group (P = 0.0056 and P = 0.037, respectively). CD25 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) double-positive T cells were significantly higher in CFAct than in CFControl (P = 0.019). A reciprocal reduction in 
CD25 CTLA-4 double-negative CD4+ T cells were seen in CFAct, CFPast, and HCA groups compared to CFControl (P = 0.001, P = 0.027, and P = 0.008, respectively). 
CFAct patient with active Mycobacterium avium complex (MAC) infection is shown as a blue circle in scatter plots. This data point was not included in the ANOVA 
analysis but is shown here to demonstrate activation and exhaustion profile of a patient with an active NTM infection that is not MABS (B) Immune marker profiling 
of CD4+ T cells by SPICE showed differences in ex vivo phenotype in the CFContro1 group compared to CFAct (P = 0.0002), CFPast (P = 0.0002), and HCA (P = 0.005). 
PMA/I stimulation resulted in minor changes in maker profile with the CFControl profile still being significantly different to CFAct (P = 0.025) and CFPast(P > = 0.018) 
though the difference with HCAwas reduced (P = 0.057). (c) SPICE dot plots show expression levels of all combinations of markers CD25, CTLA-4, and 
programmed cell death protein 1 in CD4+ T cells both ex vivo and after PMA/I stimulation in CF patient and control groups. Groups with significantly different 
expression compared to HCA (Wilcoxon rank test P < 0.05) are indicated with # symbol. Symbol color indicates significantly different group.
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with the healthy control subjects (Figures  1B,C). The T  cell 
fingerprint following PMA/I activation was not significantly dif-
ferent to ex vivo T cells (Figures 1B,C). The T cell fingerprint on 
CD8+ T cells was similar between different groups (Figure S1A in 
Supplementary Material) with significance found in CD8+ CD25 
single positive T cells ex vivo in the CFAct group and in the PMA/I-
activated CFPast group (Figure S1A in Supplementary Material). 
These data reveal a difference in systemic T cell phenotypes in 
CF patients with active or past NTM disease, particularly in CD4+ 
T  cells, compared to CF patients with more common chronic 
Pa infection. There was no difference between CF patients with 
active or past NTM disease and healthy controls in terms of T cell 
fingerprint.
Distinct T cell Function in cF Patients 
susceptible to MaBs infection
Given the differences in surface T  cell phenotypes between 
cohorts we next analyzed cytokine production post-mitogen 
stimulation. T cell cytokine production after PMA/I stimulation 
revealed a specific signature associated with NTM disease. TNFα-
producing CD4+ T cells were significantly lower in both CFAct and 
CFPast groups compared to the CFControl group (Figure 2A). TNFα 
production in CD4+ T cells was also markedly lower in both CFAct 
and CFPast compared to HCA group, though this difference did 
not reach statistical significance (Bonferroni post-hoc test). IFNγ+ 
CD4+ T cells in the CFAct group were higher than the CFControl group 
(Figure 2A). In the CD8+ subset, IFNγ+ T cells from the CFAct and 
CFPast groups were higher than the CFControl group (Figure 2A).
Polyfunctionality in CD4+ and CD8+ T cells was next examined. 
As CD107a represents degranulation and cytolytic activity, the 
expression of this marker was included in the polyfunctionality 
profile in addition to TNFα, IFNγ, and IL-2. Both CFAct and CFPast 
groups showed a unique polyfunctionality profile compared to 
both CFControls and HCA groups (Figure 2B). Both CD4+ TNFα-
producing single positive T  cells (mono-functional) and CD4+ 
TNFα+ IL2+ double-positive cells (dual-functional) were seen to 
be significantly reduced in both CFAct and CFPast groups compared 
to both control groups (Figures 2B,C). Significantly higher IFNγ 
mono-functional T cells were seen in the CFPast group compared 
to the CFControl group though there was no difference compared 
to the HCA group. There was also no difference in the number of 
triple- and quadruple-functional T cells between groups. When 
CD8+ T cell polyfunctionality was compared, significantly higher 
numbers of IFNγ producing mono-functional cells were seen in 
both CFAct and CFPast groups compared to both control groups 
though there was no significant difference in terms of overall 
polyfunctionality profile (Figure S2 in Supplementary Material). 
Total TNFα-producing CD8+ T cells were significantly higher in 
the HCA and CFControl groups compared to CFAct and CFPast groups.
Hierarchical clustering analysis of cytokine production and 
CD107a expression data showed a grouping of CFAct and CFPast 
groups, while the CFControl and HCA groups clustered together 
(Figure 3A). Based on global cytokine and CD107a expression 
profiles, patients with NTM disease (either past or present) 
could be grouped together. There was no clear separation of the 
active and past NTM infection groups indicating that based on 
all clustering variables; no global differences were seen between 
these two groups. The same pattern was observed in the chronic 
Pa infection group CFControl and the HCA group where both groups 
clustered together.
Given this common hierarchical clustering result between 
CFAct and CFPast cohorts, we next redefined the cohorts for 
subsequent data analysis. Patients who had either active or past 
NTM infection (CFAct and CFPast) were defined as the “NTM 
disease” cohort and CF patients with chronic Pa infection and 
healthy controls (CFControl and HCA) were defined as the “control” 
cohort (i.e., persons with no history of NTM infection). These 
two variables were then used as outcomes to analyze data for pre-
dictive biomarkers using GMine multivariate analysis software 
(33). CCA analysis showed significant clustering between these 
groups (Figure 3B). Biomarker analysis identified 13 significant 
predictors of “NTM disease” after correction for multiple com-
parisons (FDR) (Figure 4A). Unsurprisingly, significant predic-
tors included combinations of TNFα and IFNγ production. The 
stepwise regression model (area under the curve, AUC 100%) 
identified percentage CD8+ IL2+ TNFα− T cells and percentage 
CD8+ IFNγ+ TNFα− T cells as the best predictors of NTM disease 
(Figure 4B).
Distinct T cell Function in elderly Patients 
With active MaBs infection
To determine whether this immune profile would also be found 
in other independent disease cohorts, we next investigated elderly 
patients with active NTM infection (NTMAct). In Australia, the 
rate of notified NTM cases per 100,000 population has increased 
by approximately 17% per year between 2012 and 2015 (35). The 
reasons for this increase are unknown, and there is yet no predic-
tor to identify at-risk individuals. To determine if underlying 
immune dysfunction may be a predictive factor for NTM infec-
tion we compared NTMAct patients with elderly healthy controls 
(HCB). We found that Tregs were increased in the peripheral blood 
of elderly NTMAct patients compared to elderly HCB (Figure 5A). 
Elevated CD25 and CTLA-4 expression was also seen on CD4+ 
T cells in the NTMAct group alongside increased PD-1 expression 
on CD4+ CD25+ T cells. Analysis of the phenotypic fingerprint 
of CD25, CTLA-4, and PD-1 expression in CD4+ T cells showed 
a specific signature in NTMAct patients with elevated CD25 and 
CTLA-4 double-positive T cells as well as elevated CD25 single-
positive T  cells in the NTMAct group (Figures  5A,B). T  cells 
negative for all three markers (triple-negative) were significantly 
higher in the HCB group compared to NTMAct patients. Four 
significant phenotypic differences ex vivo and during mitogen 
stimulation were observed between the NTMAct group and HCB 
group (Figure 5C). Ex vivo CD8+ T cell fingerprint was identical 
between HCB and NTMAct cohorts (data not shown).
Mitogen stimulation and polyfunctionality analysis in the 
elderly cohorts revealed a very different profile to that seen in CF 
patients. In the NTMAct group, significantly higher TNFα produc-
tion by CD8+ T cells was observed (Figure 6A), while there was 
no difference in the number of TNFα-producing CD4+ T  cells 
between groups (Figure S3A in Supplementary Material). IFNγ 
single-positive CD8+ T cells were similar in patients and controls 
(Figures  6B,C) as was the overall polyfunctionality profile in 
CD4+ T cells (Figures S3A,B in Supplementary Material).
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FigUre 2 | Divergent T cell cytokine profiles in cystic fibrosis (CF) patients based on non-tuberculous mycobacteria (NTM) infection status. (a) Flow cytometric 
analysis of ex vivo activated CD4+ T cells show significantly lower IFNγ− TNFα+ (P = 0.026 and P = 0.030) and CD107a− TNFα+ (P = 0.026 and P = 0.027) T cells 
in CFAct and CFPast groups, respectively compared to the CFContro1 group. Differences were not significant when comparing the HCA group with ANOVA post-hoc 
testing. A similar pattern of increased TNFγ+ CD4+ T cells was seen in the HCA group. Significantly more IFNγ+ TNFα− CD4+ T cells were seen in CFAct patients 
compared to CFContro1 patients (P = 0.0315) and significantly more IFNγ+ TNFα− CD8+ T cells were seen in both CFAct and CFPast groups (P = 0.014 and 
P = 0.0047, respectively) compared to CFContro1 group. CFPast had significantly more IFNγ+ TNFα− CD8+ T cells compared to HCA(P = 0.005). CFAct patient with 
active Mycobacterium avium complex infection is shown as a blue circle in scatter plots. This data point was not included in the ANOVA analysis but is shown 
here to demonstrate cytokine profile of a patient with an active NTM infection that is not MABS (B) Polyfunctionality profiling of CD4+ T cells by SPICE showed 
differences in ex vivo functions in CFAct and CFPast groups compared to CFControl (P = 0.056 and P = 0.041, respectively) and HCA groups (P = 0.022 and 
P = 0.012, respectively). TNFα mono-expressing CD4+ T cells (blue arc) were significantly lower in the two NTM patient groups compared to the CFContro1  
and HCA groups. (c) SPICE dot plots show polyfunctionality profile of all combinations of cytokine expression in CD4+ T cells after PMA/I stimulation.  
Groups with significantly different expression compared to CFContro1 (Wilcoxon rank test P < 0.05) are indicated with # symbol. Symbol color indicates  
significantly different group.
FigUre 3 | Multivariate T cell analysis of mitogen-stimulated cytokine secretion profiles. (a) Unsupervised hierarchical clustering of mitogen-stimulated CD4+ and 
CD8+ T cell cytokine secretion profile show divergence based on non-tuberculous mycobacteria infection status. Each column represents an individual (patient/
control) and each row represents a clustering variable (cytokine secretion pattern). Clustering patterns shown according to primary group [patient with cystic fibrosis 
(CF) black, or healthy control gray] and secondary group (CFAct-light green, CFPast-dark green, CFContro1-white, and HCA-black). Clustering of CFAc and CFPast patients 
with one exception and clustering of CFContro1 and HCA with one exception. (B) Principle component analysis (PCA) and canonical co-variate analysis (CCA) show 
significant clustering (P = 0.02) of subjects by patient group. Marked overlap between CFAct and CFPast groups is seen in terms of global cytokine secretion profile 
indicating an overall similarity in secretion profile. CFContro1 group diverges further from CFAct and CFPast groups.
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FigUre 4 | Top immune biomarker candidates for diagnosis of non-tuberculous mycobacteria (NTM) infection status in cystic fibrosis cohorts. (a) Flow cytometric 
biomarkers for NTM disease state from cytokine secretion profile data (Wilcoxon rank test). Graph shows log odds ratio for each biomarker candidate for diagnosis 
of NTM disease state (negative versus exposed state) with 95% CI. (P, probability; FDR, false discover rate; AUC, area under the curve). (B) Stepwise regression 
model (forward selection) for NTM infection status. Fitted model contains 18 variables shown in table with a final AIC of −30 and an AUC 1. Plots show contribution 
of each variable to model and fitted value for each patient/control (green dots) when model is applied showing an AUC = 1.
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DiscUssiOn
The increased incidence and prevalence of NTM disease in recent 
years, warrants a more comprehensive understanding of immunity 
in susceptible individuals (7). Due to increasing antibiotic resistance 
of NTM strains and poor patient-outcomes in particular MABS, 
immunomodulatory strategies may emerge as important adjuvants 
to conventional anti-mycobacterial therapy in NTM disease. Here, 
we dissect faults in immunity in two cohorts of patients (CF and 
elderly) with NTM lung infection and matched controls to identify 
the underlying blood immune signatures of each disease. Blood was 
examined given: (i) T cells are known to traffic between the blood 
and lung (36); (ii) NTM-specific T cells have been observed in the 
blood (37); and (iii) blood is easy to access for diagnostic tests. 
The first cohort included CF patients with active NTM disease, CF 
patients with past NTM disease who had been successfully treated 
and were now in disease remission, CF patients with chronic Pa 
infection who had no history of NTM infection and a group of 
matched healthy controls. The second cohort included elderly 
patients with NTM infection and matched healthy controls. All 
control individuals in both cohorts had active or past MABS infec-
tion with the exception of one patient who had MAC infection.
The frequency of Tregs was significantly increased in CF 
patients with active and past NTM infection compared to CF 
patients with chronic Pa infection. These data contrast with the 
elderly cohort, where Tregs significantly were higher in elderly 
FigUre 5 | Evidence of CD4+ T cell activation and exhaustion in immunocompetent individuals with active non-tuberculous mycobacteria (NTM) infection.  
(a) Flow cytometric analysis of ex vivo CD4+ T cells showed significantly more Tregs in NTMAct group compared to HCB group (P = 0.028). Significantly more  
CD25+ CTLA4+ and CD25+ CTLA4− CD4+ T cells were seen in NTMAct group (P = 0.002 and P = 0.009, respectively) compared to HCB. A reciprocal increase in 
CD25− CTLA4− CD4+ T cells was seen in the HCB group (P = 0.001) compared to disease group. Higher numbers of PD1+ CD4+ T cells (P = 0.021) and CD25+ 
PD1+ CD4+ T cells (P = 0.011) were seen in the NTMAct group. CD25+ PD1− T cells were significantly higher in NTMAct group (P < 0.001) and CD25− and PD1−  
CD4+ T cells were significantly higher in HCB group (P < 0.001). (B) Phenotyping and polyfunctionality profiling of CD4+ T cells by SPICE showed differences in 
NTMAct and HCB groups directly ex vivo and post PMA/I stimulation. Phenotype profiles were significantly different between groups both ex vivo (P = 0.0013) and 
post stimulation (P = 0.022). Significantly more CD25+ CTLA4+ T cells were observed in NTMAct groups compared to HCB. (c) SPICE dot plots show phenotype 
profile of all combinations of markers CD25, CTLA4, and PD1 in CD4+ T cells both ex vivo and post PMA/I stimulation between NTMAct and HCB groups.  
Significantly different expression compared to HCB (Wilcoxon rank test P < 0.05) is indicated with # symbol.
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NTM patients compared to healthy controls. This was similarly 
observed by Hector et al., where lower number of Tregs was found 
in both the airways and peripheral blood of CF patients compared 
to healthy controls and a further reduction in Tregs was seen in 
patients with chronic Pa infection (38). The lack of difference in 
Treg percentages between CF NTM patients and healthy controls 
FigUre 6 | Divergence of CD8+ T cell cytokine profiles in immunocompetent individuals with active non-tuberculous mycobacteria (NTM) infection. (a) Flow 
cytometric analysis of ex vivo CD8+ T cells showed significantly more IFNγ− TNFα+ cells (P = 0.01) and IL2− TNFα+ cells (P = 0.048) in NTMAct compared to HCB.  
(B) Polyfunctionality profiling of CD8+ T cells shown in pie charts were not significantly different between the two groups. However, significantly higher TNFα 
mono-functional CD8+ T cells were observed in NTM patient group (P = 0.002). (c) SPICE dot plots show polyfunctionality profile of all combinations of cytokine 
expression in CD8+ T cells after PMA/I stimulation between NTMAct and HCB groups. Significantly different expression compared to HCB (Wilcoxon rank test 
P < 0.05) is indicated with # symbol.
10
Lutzky et al. Immune Anomalies in M. abscessus Infection
Frontiers in Immunology | www.frontiersin.org June 2018 | Volume 9 | Article 1319
could be an indication of an increase in Tregs following NTM 
infection. This rationale would align with our findings of elevated 
Tregs in the elderly immunocompetent patients with active NTM 
infection. Of note, increased Treg numbers have been observed 
in the peripheral blood of TB patients (39–41) indicating overlap 
between TB and NTM immunopathology.
When examining the T cell fingerprint, CF patients with active 
and past MABS infection were different to control patients with 
chronic Pa infection, though they were similar to the healthy con-
trol group. This finding suggests differences in T cell immunity 
between CF patients susceptible to MABS and CF patients who 
have no history of NTM infection.
Distinct activation and exhaustion profiles were seen in both 
patient cohorts with NTM infection compared to corresponding 
controls. Higher numbers of CD4+ T  cells co-expressing the 
activation marker CD25 and the exhaustion marker CTLA-4 
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were seen in CF patients with both active and past NTM infec-
tion. In the elderly cohort, a similar pattern of increased CD25 
and CTLA-4 co-expression was observed on CD4+ T cells. PD-1 
expression was also increased on CD4+ T  cells, suggesting an 
exhausted immune phenotype. High PD-1 expression on T cells 
associates with increased TB disease burden (26). Increased PD-1 
expression on T cells, B cells, NK cells, and monocytes has also 
been reported in patients with MAC infection (42). In mice, PD-1 
gene knockout can enhance TB resistance by preventing over-
production of IFNγ (43). However, another study showed that 
PD-1 gene knockout mice can be more susceptible to NTM infec-
tion (44). To date, the immune checkpoint CTLA-4 has not been 
studied in the context of NTM. Our data present the first finding 
of elevated CTLA-4 on T cells in NTM infection. The significance 
of this as well as elevated PD-1 expression on T cells indicates 
a degree of immune suppression in NTM infection. No PD-1 
(or CTLA-4) antibody blockade therapy has been examined 
in  vivo on TB or NTM. Future research should focus on the 
prospect of treating NTM patients using PD-1 and/or CTLA-4 
antibody blockade.
TNFα directly activates macrophages to restrict mycobacterial 
growth and induces apoptosis of infected macrophages leading 
to bacterial killing (45–47). TNFα is also essential for granuloma 
formation and disease restriction during mycobacterial patho-
genesis highlighting its importance for in  vivo control of the 
pathogen (48). Animals deficient in TNFα are highly susceptible 
to disseminated forms of TB (49). The cytokine polyfunctionality 
profiles seen in CF cohorts revealed underlying global TNFα defi-
ciencies that could explain susceptibility to NTM infection in CF 
patients. Low TNFα secretion (mono-functional TNFα-secreting 
CD4+ T cells) was seen in CF patients with both active and past 
NTM infection, while increased TNFα secreting mono-functional 
CD8+ T cells were seen in elderly patients with NTM infection. 
Given that CF patients with both active and past infection exhibit 
this TNFα deficiency in response to mitogen, it is more likely 
that this phenotype is an underlying predisposition to disease 
rather than a direct effect of the disease. The contrasting pattern 
of TNFα secretion in the two disease scenarios is significant in 
the larger context of mycobacterial pathobiology. Studies of NTM 
immunity are conflicting and show both low and high levels of 
TNFα production (12, 42, 50–52), however, these studies did not 
perform in depth mapping of cell subsets. TNFα production has 
an important role in host resistance as treatment with anti-TNFα 
therapies are associated with increased susceptibility to active TB 
and reactivation of latent TB infection (53) and is correlated with 
NTM activation in autoimmune diseases, such as rheumatoid 
arthritis, Crohn’s disease, ankylosing spondylitis, and psoriasis 
(54). Here, we have shown that the TNFα profiles can vary with 
disease setting. Thus, taking into account the individual patient 
profile is critical when interpreting these findings. Moreover, 
we have also shown that TNFα secretion levels vary according 
to cell subset and it may be specific deficiencies in certain cell 
subsets that predispose to disease. It is possible that low dose 
TNFα replacement therapy, via aerosol, for example, may aid 
standard of care in NTM treatment in CF. Indeed, other cytokine 
replacement therapies, such as IFNγ, IFNα, IL-2, GM-CSF, and 
IL-12 have shown promise against TB, MDR-TB, MAC, and 
MABS [reviewed in Ref. (53)]. Systemically administered IFNγ 
has shown the most promise for clinical use (55).
The importance of IFNγ in anti-mycobacterial immunity is 
widely accepted and extensively studied in TB (56). Reduced 
IFNγ production in NTM infection has been shown in several 
studies (51, 57, 58) though contradictory results have also been 
reported (16). Akin to TNFα, we show that IFNγ secretion varies 
with cell subset and disease scenario. In the CF NTM cohort, 
increased IFNγ secretion was seen in both CD4+ and CD8+ 
T  cells compared to healthy controls, whereas in the elderly 
NTM cohort, there was no significant increase in IFNγ-secreting 
cells in both CD4+ or CD8+ T cells. This could indicate an inad-
equate protective response rather than a deficiency of cytokine. 
Comparison of MABS infection in these two disease cohorts 
once again highlights the importance of the clinical context when 
searching for risk factors. However, one limitation of the study is 
the profiling of circulating lymphocytes which may differ to those 
at the site of disease.
The search for environmental and behavioral risk factors for 
NTM infection in CF patients has found increased acquisition in 
the tropics and decreased acquisition with macrolide treatment 
(59). Here, we show that it is also possible to define immune 
parameters in the circulatory blood that help to identify at-risk 
individuals. Specifically, we showed that CF patients can stratify 
CF into two groups based on Treg frequencies, CD4+ T cell sur-
face phenotype (CD25 and CTLA-4) and cytokine production by 
CD4+/CD8+ T cells (IFNγ, TNFα, CD107a, and IL-2), with at-risk 
patients exhibiting a distinct deficiency in TNFα. We suggest that 
this immune signature could be further refined and validated in 
independent cohort studies, and then ultimately developed for 
use as a diagnostic tool to identify individuals who are at high risk 
of developing NTM infection. Targeted behavioral interventions 
for at-risk patients may subsequently decrease the risk of NTM 
acquisition from the environment or infected patients.
The role of CD8+ T cells in NTM infection in humans remains 
unclear. Research in TB in primate and mouse models has shown 
that CD8+ T  cells are important in controlling experimental 
infection. However, the precise mechanism by which they con-
tribute to protection is unknown (60). Regulatory CD8+ T cells 
have been identified in human TB, though their role in protection 
is also not clear (60).
This study specifically focused on MABS infection. It is impor-
tant to highlight that the CF patient with active MAC infection 
(shown as a blue circle in Figures 1A and 2A) exhibited a T cell 
fingerprint and T cell functional profile very similar to patients 
with MABS infection (note; this patient was not included in sta-
tistical analysis). Additionally, it is also important to note the 2 of 
6 CF MABS patients and 3 of 10 elderly MABS patients either had 
a previous history of MAC infection or subsequently developed 
MAC infection. This tentatively suggests that the susceptibility to 
NTM infection may occur through a common immune dysfunc-
tion pathway, although further antigen-specific immune studies 
are required to validate this hypothesis. If NTM-specific immune 
dysfunction is common in the individuals, targeted immuno-
therapies may help in correcting this deficit.
Limitations of this study include the small sample size due 
to restrictions in patient recruitment within a confined study 
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duration. An additional, larger patient cohort will be essential to 
validate our predictive model. Limitations in sample volumes also 
restricted the analysis to ex vivo phenotyping and mitogen-activa-
tion signatures. Thus, antigen-specific immune responses were not 
conducted in this study. However, further research is warranted 
given the identification of significant global immune anomalies in 
this exploratory study. Anomalies in mitogen-triggered activation 
signatures in the global T cell compartment suggest an underlying 
immune deficiency in the patients that would likely translate to 
NTM-specific responses as seen in TB (61, 62).
In summary, our study presents the first data on immune 
checkpoint expression on T cell subsets in human MABS infec-
tion as well as the first comparison of T  cell polyfuntionality 
between CF and non-CF patient groups with MABS infection in 
response to mitogen stimulation. We show that MABS infection 
in two different patient groups’ exhibit specific immune pheno-
types and show dysregulation in type 1 cytokine production and a 
global decrease in T cell “quality.” In CF patients, TNFα-mediated 
immunity may hold the key to understanding the increased risk 
of MABS infection and guide future therapeutic interventions. 
In elderly individuals, interference with checkpoint molecules 
(PD-1 and CTLA-4) may guide future therapeutic interventions. 
Collectively, the study has revealed many potential associations 
between T  cell phenotype and individuals at risk of MABS 
infection. The idea of an underlying immune dysfunction which 
predisposes certain individuals to NTM infection is attractive 
but very speculative. Larger populations and further functional 
experiments will be required to validate this hypothesis.
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